Compare WT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WT | ADPT |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 2011 | 2019 |
| Metric | WT | ADPT |
|---|---|---|
| Price | $19.04 | $13.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $17.67 | ★ $17.78 |
| AVG Volume (30 Days) | ★ 3.0M | 1.7M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 127.27 | 63.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $493,753,000.00 | $276,976,000.00 |
| Revenue This Year | $35.04 | $3.98 |
| Revenue Next Year | $8.68 | $22.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 15.43 | ★ 54.77 |
| 52 Week Low | $9.24 | $8.50 |
| 52 Week High | $19.29 | $20.76 |
| Indicator | WT | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 65.87 | 46.90 |
| Support Level | $15.69 | $12.22 |
| Resistance Level | N/A | $15.38 |
| Average True Range (ATR) | 0.80 | 0.81 |
| MACD | 0.20 | 0.03 |
| Stochastic Oscillator | 94.19 | 37.79 |
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.